Key facts
- Status: Out of Business.
- ·Watchlist + deal alerts for Axiom Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Axiom Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axiom Bio
Developer of diagnostic and rescue therapies designed to reverse opioid overdose and reduce post-crisis stress. The company combines naloxone for rapid recovery with oxytocin for emotional stabilization and research partnerships, enabling healthcare providers to treat overdose effectively while addressing psychological impact and lowering relapse risk.
- Sector
- Healthcare
- HQ
- Gainesville, FL, United States
- Founded
- 2025
- Website
- axiom-bio.com/
- Ownership
- Out of Business
Axiom Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axiom Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axiom Bio in its N-PORT filings yet. We sweep new filings monthly.